Biohaven Ltd.
Biohaven Ltd. (BHVN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BHVN · as of Jun 8, 2026
Key Statistics
Explore Biohaven Ltd. Data
bhvn stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 25 · Buy rate: 72.0%
The BHVN analyst consensus is Buy, based on ratings from 25 Wall Street analysts over the past 3 months. The average 12-month price target is $17.60, representing +57.99% upside from the current price of $11.14.
Competitors & Peers
bhvn competitorsBHVN
ABCL
CLDX
IMCR
IMNM
NTLAStock Performance
Full HistoryAbout Biohaven Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
what is biohaven ltd. · bhvn stock overview · biohaven ltd. company profile · who is biohaven ltd. ceo · bhvn NYSE · biohaven ltd. headquarters · biohaven ltd. business segments
About Stock Overview & Key Data
Biohaven Ltd. (BHVN) is a Healthcare company in the Biotechnology industry, listed on NYSE since Sep 23, 2022. As of the latest trading session, BHVN stock price is $11.14, with a market capitalization of $1.2B. The stock has returned -36.73% over the past 12 months and -4.34% year-to-date.
According to 25 Wall Street analysts, the consensus rating for Biohaven Ltd. stock is Buy, with an average 12-month price target of $17.60. In fiscal year 2025, Biohaven Ltd. reported revenue of — and net income of -$738.8M. For detailed data — including Biohaven Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Biohaven Ltd. (BHVN) stock price is $11.14. The stock is traded on NYSE under the ticker symbol BHVN. The 52-week range is $7.48 – $18.57.